更新版快速诊断试验用于革兰阴性菌血症后抗生素治疗时间的评估
该单中心回顾性准实验研究比较了BCID2多重PCR面板实施前后成人革兰阴性菌血流感染患者的结局,共纳入180例患者。结果显示BCID2组有效治疗时间中位数从4小时降至1小时(P=0.004),ESBL亚组中适当治疗时间也显著缩短,但死亡率与住院时长无显著差异。
要点
- BCID2实施后有效抗生素治疗时间中位数由4小时缩短至1小时(P=0.004)。
- ESBL亚组中BCID2显著缩短有效治疗时间(0.5 vs 3小时,P=0.006)和适当治疗时间(16 vs 44小时,P=0.016)。
- BCID2组与BCID组30天死亡率(6.7% vs 8.9%,P=0.756)和住院时长(10 vs 14天,P=0.134)无显著差异。
核心结论
- 实施BCID2面板可显著缩短革兰阴性菌血流感染的有效抗生素治疗时间,尤其在耐药菌感染中。
研究设计与样本
- 单中心、回顾性、准实验研究,比较BCID2实施前后成人革兰阴性菌血流感染患者,共纳入180例(BCID组和BCID2组各90例)。
主要发现
- BCID2组有效治疗时间中位数1小时,BCID组4小时(P=0.004)。
- BCID2组适当治疗时间中位数25小时,BCID组49小时(P=0.627)。
- ESBL亚组中BCID2组有效治疗时间0.5小时,BCID组3小时(P=0.006);适当治疗时间16小时 vs 44小时(P=0.016)。
- 30天死亡率BCID2组6.7%,BCID组8.9%(P=0.756);住院时长BCID2组10天,BCID组14天(P=0.134)。
临床怎么用
- 采用BCID2面板可加速革兰阴性菌血症的抗生素调整,尤其对产ESBL耐药菌感染患者可能获益更明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Rapid pathogen identification optimizes antibiotic therapy in bacteremia and can be achieved through molecular-based diagnostic tests. This study assesses the clinical impact after the implementation of an updated multiplex PCR panel (BIOFIRE Blood Culture Identification 2, BCID2). This single-center, retrospective, quasi-experimental study compared outcomes in adult patients with gram-negative bloodstream infections (GN-BSIs) pre and post BCID2 implementation. Data were collected from 1 March 2022 to 1 March 2024. Patients were included if they were ≥18 years of age, had a gram-negative organism identified by the panels, and received ≥48 h of antibiotics. The primary outcome was time to effective antimicrobial therapy; secondary outcomes included time to appropriate therapy, 30-day mortality, and hospital length of stay. A total of 180 patients were included (90 per BCID and BCID2 groups). Baseline characteristics were similar: median age 62 years, mostly non-critically ill, Charlson Comorbidity Index 4, and Pitt Bacteremia score 1 in both groups. Median time to effective therapy was reduced in the BCID2 vs BCID group (1 vs 4 h, P = 0.004) as well as time to appropriate therapy (25 vs 49 h, P = 0.627). In the ESBL subgroup, BCID2 significantly reduced time to effective therapy (0.5 vs 3 h, P = 0.006) and time to appropriate therapy (16 vs 44 h, P = 0.016). There was no significant difference in mortality (6.7% vs 8.9%, P = 0.756) or length of stay (10 vs 14 days, P = 0.134) between BCID and BCID2 groups. The implementation of BCID2 significantly reduced time to effective therapy in GN-BSIs, particularly among resistant organisms. IMPORTANCE: This study evaluated the impact of transitioning from BCID to BCID2 panel in gram-negative bloodstream infections to address gaps in resistance detection and assess whether expanded molecular diagnostics improve time to antibiotic therapy and clinical outcomes.
引用
- Hussein R, Lee L, Nog R, et al. Evaluation of time to antibiotic therapy after implementation of an updated rapid diagnostic test for gram-negative bacteremia. J Clin Microbiol. 2026. PMID: 42671186. doi:10.1128/jcm.00328-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。